MSK Head and Neck Cancer: Thyroid Cancer Research Update | Memorial Sloan Kettering Cancer Center
The safety and feasibility of active surveillance for patients with low‑risk papillary thyroid cancer.
Memorial Sloan Kettering Cancer Center experts present new evidence supporting active surveillance for low‑risk papillary thyroid cancer, describe mutation profiles of high‑grade follicular cell‑derived nonanaplastic thyroid carcinoma (HGFCTC), update on redifferentiation therapy for radioactive iodine‑refractory disease, and report promising benefits of larotrectinib in NTRK‑fusion‑positive thyroid cancer.
Using surveillance instead of immediate surgery reduces overtreatment and associated complications while maintaining excellent long‑term survival for low‑risk disease.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management